Skip to main content
Christopher Martin, MD, Internal Medicine, New York, NY

Christopher Martin MD CAQSM

Sports Medicine (Non-Surgical)


Physician - Sports Medicine

Join to View Full Profile
  • 130 E 67th StNew York, NY 10065

  • Phone+1 212-759-4553

Dr. Martin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Ross University School of Medicine
    Ross University School of MedicineClass of 2015

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2021 - 2026
  • LA State Medical License
    LA State Medical License 2019 - 2021
  • NJ State Medical License
    NJ State Medical License 2016 - 2020
  • Sports Medicine
    American Board of Emergency Medicine Sports Medicine
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine

Press Mentions

  • ADC Therapeutics to Participate in Cowen 41st Annual Health Care Conference
    ADC Therapeutics to Participate in Cowen 41st Annual Health Care ConferenceFebruary 25th, 2021
  • ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and Other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore
    ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and Other ADCs for Hematologic and Solid Tumor Indications in Greater China and SingaporeDecember 14th, 2020
  • ADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
    ADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaNovember 20th, 2020
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: